Methotrexate treatment does not contribute to the increased risk for interstitial lung disease observed among patients with rheumatoid arthritis, according to data from a Danish cohort study presented at the EULAR 2020 E-congress.
Study results presented at the EULAR 2020 E-Congress suggest that implementing an individualized therapeutic drug monitoring strategy at the time of infliximab initiation does not improve remission rates in patients with a range of inflammatory diseases.
The JAK1 selective inhibitor upadacitinib improves disease activity to a greater degree than abatacept in rheumatoid arthritis patients with previous biologic exposure, show data presented at the EULAR 2020 E-Congress.
There were a variety of sessions at the EULAR 2020 E-Congress talking about the risk factors associated with COVID-19 hospitalization among patients with rheumatic conditions, as data from the COVID-19 Global Rheumatology Alliance registry and contributing national registries become available.
Phase 2 study anaGO findings presented in a poster at the EULAR 2020 E-congress reveal that patients with difficult-to-treat gout who receive the interleukin-1 receptor antagonist anakinra report comparable levels of pain reduction to those given triamcinolone.
Real-world data from the JAKPOT study suggest slightly higher retention with JAK inhibitors than TNF inhibitors in patients with rheumatoid arthritis, but not significantly so due to rates varying widely from country to country.
The SELECT-PsA-1 and SELECT-PsA-2 trials presented at the EULAR 2020 E-Congress have demonstrated that upadacitinib may be a promising treatment option for psoriatic arthritis patients with and without prior exposure to biologic agents.
Findings from the ADVOCATE trial suggest that patients with antineutrophil cytoplasmic antibody-associated vasculitis who are treated with avacopan are more likely to experience sustained remission than those given glucocorticoids.
Temporary discontinuation of etanercept could be an option for around a quarter of patients with nonradiographic axial spondyloarthritis who achieve stable inactive disease, delegates were told at the EULAR 2020 E-Congress.
Patients with rheumatoid arthritis who are treated with TNF inhibitors have a significantly lower risk for venous thromboembolism than those given conventional DMARDs, suggests an analysis of the German RABBIT registry.
Secukinumab provides sustained improvement in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations who have had an inadequate response to nonsteroidal anti-inflammatory drugs, show 52-week data from the MAXIMISE trial.
Withdrawal of tumor necrosis factor inhibitors leads to a “steep increase” in flare risk among patients with rheumatoid arthritis (RA) in longstanding remission, report the ARCTIC REWIND investigators.